CIK 0001619856 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Caribou Biosciences, Inc.
Sign in to watch- Ticker
- CRBU
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 453728228
- Phone
- 510-982-6030
- Business address
- 2929 7TH STREET, SUITE 105, BERKELEY, CA, 94710
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-20 | Kanner Steven Chief Scientific Officer | Grant or award · Option to purchase Common Stock | +153,000 | 153,000 | ||
| 2024-02-20 | Zheng Ran Director | Grant or award · Option to purchase Common Stock | +39,500 | 39,500 | ||
| 2024-02-20 | Whiting Nancy Director | Grant or award · Option to purchase Common Stock | +39,500 | 39,500 | ||
| 2024-02-20 | Sacks Natalie Director | Grant or award · Option to purchase Common Stock | +39,500 | 39,500 | ||
| 2024-02-20 | Richardson-Heron Dara Director | Grant or award · Option to purchase Common Stock | +39,500 | 39,500 | ||
| 2024-02-20 | JOHNSON DAVID LEE Director | Grant or award · Option to purchase Common Stock | +39,500 | 39,500 | ||
| 2024-02-20 | GUGGENHIME ANDREW Director | Grant or award · Option to purchase Common Stock | +39,500 | 39,500 | ||
| 2024-02-20 | Braunstein Scott Director | Grant or award · Option to purchase Common Stock | +39,500 | 39,500 | ||
| 2024-02-06 | Kanner Steven Chief Scientific Officer | Option exercise | +30,577 | $2.69 | $82K | 354,037 |
| 2024-02-06 | Kanner Steven Chief Scientific Officer | Option exercise · Option to purchase Common Stock | −30,577 | 21,623 | ||
| 2024-01-08 | Kelly Timothy P Chief Technology Officer | Grant or award · Option to purchase Common Stock | +300,000 | 300,000 | ||
| 2023-06-08 | Haurwitz Rachel E. President and CEO | Option exercise | +10,000 | $2.96 | $30K | 40,000 |
| 2023-06-08 | Haurwitz Rachel E. President and CEO | Option exercise · Option to purchase Common Stock | −10,000 | 96,350 | ||
| 2023-03-20 | Haurwitz Rachel E. President and CEO | Option exercise | +10,000 | $2.96 | $30K | 30,000 |
| 2023-03-20 | Haurwitz Rachel E. President and CEO | Option exercise · Option to purchase Common Stock | −10,000 | 106,350 | ||
| 2023-02-21 | Haurwitz Rachel E. President and CEO | Grant or award · Option to purchase Common Stock | +510,500 | 510,500 | ||
| 2023-02-21 | Kanner Steven Chief Scientific Officer | Grant or award · Option to purchase Common Stock | +131,000 | 131,000 | ||
| 2023-02-21 | Richardson-Heron Dara Director | Grant or award · Option to purchase Common Stock | +21,500 | 21,500 | ||
| 2023-02-21 | Khan Ruhi Ahmad Chief Business Officer | Grant or award · Option to purchase Common Stock | +131,000 | 131,000 | ||
| 2023-02-21 | Sacks Natalie Director | Grant or award · Option to purchase Common Stock | +21,500 | 21,500 |
Page 4 of 9 · 177 trades